Clinical trials: Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome With Constipation
A Study of Virtual Reality and Linaclotide for IBS-C
The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication)…
- Trial name
- IBSC-VR (NCT05796388)
- Testing
- Virtual Reality
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Functional Constipation, Irritable Bowel Syndrome
Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease
The purpose of this project is to study the the efficacy and safety of probiotics implantation through infusion during colonoscopy in the treatment of functional constipation and irritable bowel syndrome.
- Conditions
- Functional Constipation, Irritable Bowel Syndrome, Probiotics, Colonoscopy
- Trial name
- CPIFGD (NCT05366335)
- Testing
- Live Combined Bifidobacterium and Lactobacillus, Normal saline, Basic treatment
- Where
- China
- Volunteers
- 160 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Irritable Bowel Syndrome With Diarrhea
Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation
This study aim to compare the efficacy of nitazoxanide in 2-week course of treatment with rifaximin in treating diarrhea associated with IBS.
- Trial name
- NCT05453916
- Testing
- Nitazoxanide 500Mg Oral Tablet, Rifaximin 550Mg Tab
- Where
- Egypt
- Sponsor
- Sadat City University
Constipation-predominant Irritable Bowel Syndrome
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test.
- Trial name
- C-IBS (NCT00945334)
- Testing
- Neomycin, Rifaximin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Mark Pimentel, MD
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
The purpose of this study is to determine whether olorinab is a safe and effective treatment for abdominal pain in participants with irritable bowel syndrome (IBS).
- Trial name
- CAPTIVATE (NCT04043455)
- Testing
- Olorinab
- Where
- 69 sites in United States
- Volunteers
- 273 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
This study will evaluate the safety, tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00215566
- Testing
- DDP733
- Where
- 15 sites in Canada
- Volunteers
- 90 people
- Sponsor
- Dynogen Pharmaceuticals
Irritable Bowel Syndrome Characterized by Constipation
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
Consecutive patients with Irritable Bowel Syndrome with Constipation (IBS-C) will be recruited from the outpatient clinics of the University of Michigan Health System.
- Trial name
- NCT03687814
- Testing
- Low FODMAP diet/PEG 3350
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of Michigan
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome
Irritable bowel syndrome is characterized by the presence of chronic, recurrent abdominal pain, alterations in bowel habits, and abdominal distension. The medical diagnosis is made using the Rome IV criteria.
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Mixed
- Trial name
- NCT07103772
- Testing
- Ananá
- Where
- Mexico
- Volunteers
- 94 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Irritable Bowel Syndrome
Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome With Constipation
Irritable bowel syndrome (IBS) is a complex multifactorial functional disorder, whose pathophysiology is largely associated to an impairment of the intestinal microbiota composition, namely dysbiosis.
- Trial name
- TRAMIR-S (NCT05803993)
- Testing
- Fecal microbiota transplantation (FMT) Single FMT infusion
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Irritable Bowel Syndrome Characterized by Constipation
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
- Trial name
- IBS-C (NCT02493452)
- Testing
- Plecanatide
- Where
- 191 sites in United States
- Volunteers
- 1,135 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
- Trial name
- NCT00399542
- Testing
- Lubiprostone
- Volunteers
- 581 people
- Sponsor
- Sucampo Pharma Americas, LLC
Constipation
Constipation Associated With Irritable Bowel Syndrome (IBS-C)
Multi-centre, double-blind, randomised, placebo-controlled, parallel group study.
- Trial name
- NCT00796354
- Testing
- MOVICOL, Sugar Pill
- Where
- 21 sites in Czechia, France and 5 more
- Volunteers
- 210 people
- Sponsor
- Norgine
IBS, IBS - Irritable Bowel Syndrome
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
The aim of this study is to better understand how tenapanor affects the metagenomics and metabolomics of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor is the newest FDA-approved agent for IBS-C.
- Trial name
- NCT05995899
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kyle Staller, MD, MPH
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome Characterized by Constipation
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
- Trial name
- NCT02837783
- Testing
- Linaclotide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
The goal of this clinical trial is to learn if plecanatide can improve bowel function and relieve symptoms of irritable bowel syndrome with constipation (IBS-C) in children and adolescents aged 6 to <18 years.
- Trial name
- (IBS-C) (NCT03596905)
- Testing
- Plecanatide
- Where
- 35 sites in United States
- Volunteers
- 218 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.
- Trial name
- NCT06553547
- Testing
- Tenapanor
- Where
- 20 sites in United States
- Volunteers
- 72 people
- Sponsor
- Ardelyx
Constipation, Chronic Idiopathic Constipation
The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation is a common gastrointestinal motility disorder that is often chronic, negatively affects patients' daily lives. Constipation occurs when bowel movements become difficult or less frequent.This study is being done to…
- Conditions
- Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
- Trial name
- NCT03054506
- Testing
- CSP01, Carboxymethylcellulose (CMC)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital